Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) With Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-1540
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study

Bone Marrow Transplantation
TransplantationHematology
1997English

A Phase I and Pharmacokinetic Study of Intraperitoneal Topotecan

British Journal of Cancer
Cancer ResearchOncology
2001English

Pegfilgrastim in Autologous Stem Cell Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Phase I Trial and Pharmacokinetic Study of High-Dose Clofarabine and Busulfan and Allogeneic Stem Cell Transplantation in Adults With High-Risk and Refractory Acute Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Phase I Study of Tandem High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Rescue for Children With Recurrent Brain Tumors: A Pediatric Blood and Marrow Transplant Consortium Study

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2010English

Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

Journal of Clinical Pharmacology
Pharmacology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy